Nuo Therapeutics, Inc.

Nuo Therapeutics, Inc. entered into an Amended and Restated Loan and Security Agreement, increasing its aggregate loan commitment to $2.0 million. The company received $675,000 in interim funding, with an additional $325,000 available by September 30, 2026, for general working capital. The loan, which includes participation from board members and significant shareholders, carries an annual interest rate of 12% and is secured by all company assets. Interest is payable in warrants, and principal repayment begins in March 2027.

Nuo Therapeutics announced strong financial results for Q1 2026, with total revenues increasing by 169% year-over-year to approximately $1.3 million. The company also significantly reduced its net operating loss to $446,000 from $745,000 in the prior year. Nuo reported robust demand for its Aurix product and favorable market response to improved Medicare reimbursement. Additionally, the company secured a $1.0 million Loan and Security Agreement to support growth and working capital.

Nuo Therapeutics reported a significant increase in total revenue for Q1 2026, rising 169% to $1.30 million, and a 17% improvement in net loss to $(0.62) million. The company also secured $1.0 million in new notes payable in January 2026. However, cash balances decreased, total liabilities increased, and management expressed substantial doubt about its ability to continue as a going concern due to insufficient resources for the next 12 months.